摘要 |
Provided are compositions and methods for the treatment of hematological conditions, in particular haematopoietic and lymphoid malignancies including CD99+ acute myelogenous leukemias (AML), myelodysplasia syndromes (MDS) and T-cell neoplasms, which comprise one or more antibody that (a) binds to the extracellular domain of CD99, (b) ligates myeloid or lymphoid malignant cell-surface expressed CD99, (c) promotes the capping/clustering/aggregation myeloid or lymphoid malignant cell-surface expressed CD99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated CD99+ myeloid or lymphoid malignant cells. Disclosed methods include methods for identifying patients afflicted with a haematopoietic or lymphoid malignancy that are susceptible to treatment with an anti- CD99 antibody by detecting the elevated expression of CD99 in a tissue sample or myeloid or lymphoid malignant cell from a patient and for treating a patient afflicted with a haematopoietic or lymphoid malignancy exhibiting elevated CD99 gene and or cell-surface protein expression by administering a composition comprising an anti-CD99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and a chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5- azacytidine, and decitabine. |
申请人 |
MEMORIAL SLOAN-KETTERING CANCER CENTER |
发明人 |
PARK, Christopher, Y.;CHUNG, Stephen, Shiu-Sah;TAVAKKOLI, Montreh |